Composition of Gut Microbiota of Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection Taking Antiretroviral Therapy in Zimbabwe.
Adolescent
Anti-Retroviral Agents
/ adverse effects
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes
Child
Cross-Sectional Studies
Dysbiosis
/ epidemiology
Female
Gastrointestinal Microbiome
/ drug effects
HIV
HIV Infections
/ drug therapy
Humans
Male
RNA, Ribosomal, 16S
/ genetics
Sequence Analysis, RNA
Viral Load
Zimbabwe
/ epidemiology
Africa
HIV infection
antiretroviral therapy
children
gut microbiota
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
14 01 2020
14 01 2020
Historique:
received:
27
05
2019
accepted:
11
09
2019
pubmed:
25
9
2019
medline:
22
9
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
Human immunodeficiency virus (HIV) infection causes impairment of the gastrointestinal barrier, with substantial depletion of CD4+ T cells in the gut. Antiretroviral therapy (ART) restores CD4+ counts and may have beneficial effects on gut microbiota in adults. Little is known about effect of long-term ART on gut microbiome in HIV-infected children. We investigated composition of gut microbiota in HIV-infected and -uninfected children and assessed associations between gut microbiota and patient characteristics. In a cross-sectional study, rectal swabs were collected from 177 HIV-infected and 103 HIV-uninfected controls. Gut microbial composition was explored using 16S ribosomal ribonucleic acid sequencing. Human immunodeficiency virus-infected children had significantly lower alpha-diversity and higher beta-diversity compared to HIV-uninfected. No association was observed between microbiome diversity and CD4+ T-cell count, HIV viral load, or HIV-associated chronic lung disease. We found enriched levels of Corynebacterium (P < .01), Finegoldia (P < .01), and Anaerococcus (P < .01) in HIV-infected participants and enrichment of Enterobacteriaceae (P = .02) in participants with low CD4+ counts (<400 cells/mm3). Prolonged ART-treatment (≥10 years) was significantly associated with a richer gut microbiota by alpha diversity. Human immunodeficiency virus-infected children have altered gut microbiota. Prolonged ART may restore the richness of the microbiota closer to that of HIV-uninfected children.
Sections du résumé
BACKGROUND
Human immunodeficiency virus (HIV) infection causes impairment of the gastrointestinal barrier, with substantial depletion of CD4+ T cells in the gut. Antiretroviral therapy (ART) restores CD4+ counts and may have beneficial effects on gut microbiota in adults. Little is known about effect of long-term ART on gut microbiome in HIV-infected children. We investigated composition of gut microbiota in HIV-infected and -uninfected children and assessed associations between gut microbiota and patient characteristics.
METHODS
In a cross-sectional study, rectal swabs were collected from 177 HIV-infected and 103 HIV-uninfected controls. Gut microbial composition was explored using 16S ribosomal ribonucleic acid sequencing.
RESULTS
Human immunodeficiency virus-infected children had significantly lower alpha-diversity and higher beta-diversity compared to HIV-uninfected. No association was observed between microbiome diversity and CD4+ T-cell count, HIV viral load, or HIV-associated chronic lung disease. We found enriched levels of Corynebacterium (P < .01), Finegoldia (P < .01), and Anaerococcus (P < .01) in HIV-infected participants and enrichment of Enterobacteriaceae (P = .02) in participants with low CD4+ counts (<400 cells/mm3). Prolonged ART-treatment (≥10 years) was significantly associated with a richer gut microbiota by alpha diversity.
CONCLUSIONS
Human immunodeficiency virus-infected children have altered gut microbiota. Prolonged ART may restore the richness of the microbiota closer to that of HIV-uninfected children.
Identifiants
pubmed: 31549151
pii: 5572969
doi: 10.1093/infdis/jiz473
pmc: PMC7457326
doi:
Substances chimiques
Anti-Retroviral Agents
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-492Subventions
Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U01 AI110466
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG009824
Pays : United States
Investigateurs
Carmen Gonzalez-Martinez
(C)
Katharina Kranzer
(K)
Elizabeth L Corbett
(EL)
Hilda Mujuru
(H)
Sarah Rowland-Jones
(S)
Andrea M Rehman
(AM)
Tsitsi Bandason
(T)
Ethel Dauya
(E)
Edith Majonga
(E)
Beauty Makamure
(B)
Gugulethu Newton Mapurisa
(GN)
Brewster Wisdom Moyo
(BW)
Lucky Gift Ngwira
(LG)
Jamie Rylance
(J)
Victoria Simms
(V)
Helen Anne Weiss
(HA)
Louis-Marie Yindom
(LM)
Slee Mbhele
(S)
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
AIDS. 2017 Mar 27;31(6):857-862
pubmed: 28118207
Curr Opin Microbiol. 2013 Jun;16(3):255-61
pubmed: 23831042
Sci Transl Med. 2013 Jul 10;5(193):193ra91
pubmed: 23843452
Cell Host Microbe. 2016 Mar 9;19(3):311-22
pubmed: 26962942
Gut Microbes. 2014 Jul 1;5(4):562-70
pubmed: 25078714
Emerg Infect Dis. 2002 Jan;8(1):92-3
pubmed: 11749759
Trials. 2017 Dec 28;18(1):622
pubmed: 29282143
PLoS One. 2011 Feb 28;6(2):e17035
pubmed: 21386965
Annu Rev Med. 2011;62:141-55
pubmed: 21090961
Curr Opin HIV AIDS. 2016 Mar;11(2):182-90
pubmed: 26679414
Nat Rev Microbiol. 2017 Jan;15(1):55-63
pubmed: 27694885
PLoS One. 2010 Jan 05;5(1):e8578
pubmed: 20052417
Mucosal Immunol. 2014 Jul;7(4):983-94
pubmed: 24399150
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106
Microbiome. 2013 Oct 12;1(1):26
pubmed: 24451087
Curr Opin HIV AIDS. 2018 Jan;13(1):38-44
pubmed: 29045253
J Infect Dis. 2015 Jan 1;211(1):19-27
pubmed: 25057045
Sci Rep. 2018 Mar 22;8(1):5078
pubmed: 29567959
Clin Pharmacol Ther. 2016 Jun;99(6):600-11
pubmed: 26940481
EBioMedicine. 2016 Jan 28;5:135-46
pubmed: 27077120
Am J Gastroenterol. 2012 Dec;107(12):1913-22
pubmed: 23044767
PLoS Pathog. 2014 Feb 20;10(2):e1003829
pubmed: 24586144
Cell Host Microbe. 2013 Sep 11;14(3):329-39
pubmed: 24034618
J Exp Med. 2004 Sep 20;200(6):749-59
pubmed: 15365096
Patholog Res Int. 2011 Apr 26;2011:247923
pubmed: 21559197
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4516-22
pubmed: 20534432
Clin Exp Allergy. 2014 Jun;44(6):842-50
pubmed: 24330256
Mucosal Immunol. 2015 Jul;8(4):760-72
pubmed: 25407519
AIDS Res Hum Retroviruses. 2019 Mar;35(3):229-235
pubmed: 29877092
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Ecol Evol. 2014 Sep;4(18):3514-24
pubmed: 25478144
Ann Am Thorac Soc. 2015 Jan;12(1):70-8
pubmed: 25474359
Front Microbiol. 2018 Sep 19;9:2147
pubmed: 30283410
AIDS. 2014 Mar 13;28(5):753-60
pubmed: 24335481
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944164
Pan Afr Med J. 2014 Mar 07;17:179
pubmed: 25392725
Emerg Microbes Infect. 2018 Jun 22;7(1):113
pubmed: 29934497
Environ Microbiol. 2018 Jan;20(1):402-419
pubmed: 29322681
Curr Opin HIV AIDS. 2018 Jan;13(1):73-80
pubmed: 29045252
AIDS. 2015 Nov 28;29(18):2409-18
pubmed: 26355675